In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL -385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71% vs 62%, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6% vs 41%, respectively (P = 0.0006 by log-rank testing). Treatmentrelated mortality was higher after allotransplant than autotransplant: 23% vs 6%, respectively (P = 0.001 by 2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and year of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95% CI: 0.309-1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95% CI: 0.043-0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95% CI: 0.527-3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy. Keywords: non-Hodgkin's lymphoma; autotransplant; allotransplant Autologous blood and marrow transplantation (autoBMT) is potentially curative in patients with chemotherapysensitive relapsed aggressive non-Hodgkin's lymphoma (NHL) 1-3 and improves survival compared with chemotherapy alone.
Autologous blood and marrow transplantation (autoBMT) is potentially curative in patients with chemotherapysensitive relapsed aggressive non-Hodgkin's lymphoma (NHL) [1] [2] [3] and improves survival compared with chemotherapy alone. 1, 2, 4 . Nonetheless, autoBMT is still associated with a moderately high risk of relapse. [1] [2] [3] [4] [5] [6] Allogeneic bone marrow transplantation (alloBMT) is a potentially attractive option for the treatment of relapsed NHL, because it provides, in addition to the intensive therapy regimen, a graftversus-lymphoma effect that may reduce the risk of relapse. Its role in the management of patients with relapsed NHL must be explored because of higher treatment-related mortality and morbidity associated with acute and chronic graft-versus-host disease.
Few studies have compared autoBMT and alloBMT for the treatment of relapsed NHL. [7] [8] [9] In a review of 938 autotransplants and 122 allotransplants for relapsed aggressive NHL from the European BMT (EBMT) registry, progression-free survival between autoBMT and alloBMT was equivalent. 8 The incidence of relapse was also similar. Twenty-three percent of patients relapsed or progressed after alloBMT compared with 38% of patients after autoBMT. Treatment-related mortality was higher after alloBMT. During the follow-up period, 28% of patients died from transplant-related complications compared with 14% after autoBMT. This study did not comment specifically on overall survival. A single institution prospective trial compared autoBMT and alloBMT for relapsed or refractory NHL. 9 Patients aged 55 or under with an HLAmatched sibling were offered alloBMT while patients without an HLA-matched sibling or those aged 55-60 years were offered autoBMT. Sixty-six patients (35 autoBMT and 31 alloBMT) were enrolled in the study. Progressionfree survival was equivalent between the two groups; lower risk of relapse after alloBMT was offset by higher treatment-related mortality.
Here, we report the results of all alloBMT and autoBMT performed for NHL in the province of Ontario between 1986 and 1997. In Ontario, the provincial government provides universal health care coverage for all permanent residents. Residents have access to BMT at five centers in the province. In 1986, the centers formed the Ontario Blood and Marrow Transplant Network and agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant, but be referred for allotransplant if they had marrow involvement or an inadequate marrow/stem cell harvest provided they had a related donor. Patient data were recorded in a database. We reviewed this database to compare allogeneic and autologous BMT for NHL with respect to overall survival, rate of relapse and treatment-related mortality. In addition, a matched comparison between auto and allo-transplant patients was performed.
Materials and methods

Definitions
Overall survival was measured in months and was defined as duration from transplant until death from any cause. Disease-free survival was measured in months and defined as duration from the day of transplant to the date of relapse or death from any cause. Treatment-related mortality was defined as death attributable to complications from the transplant, which was usually within the first 100 days. Disease status at transplant was recorded as complete response, partial response, and relapse or persisting disease. Patients with disease in complete response had no evidence of disease at transplant after salvage therapy. Patients with disease in partial response at transplant had у50% decrease in tumor bulk after salvage therapy but measurable disease at transplant. Patients in relapse or with persisting disease had the BMT performed at relapse without receiving other salvage treatment.
Lymphomas were divided into aggressive and indolent subtypes. Indolent subtypes included working formulation categories A, B and C. Aggressive lymphomas included working formulation categories D-H, and J. In addition, transformed lymphoma (n = 24), Ki positive lymphoma (n = 4), mantle cell lymphoma (n = 4) and T cell rich B cell lymphoma (n = 3) were classified as aggressive lymphomas. Patients with lymphoblastic lymphoma were excluded from the analysis.
No attempt was made to verify the histologic diagnoses by a centralized slide review process.
Patients and database
Five centres in the province of Ontario offer bone marrow transplantation for NHL. Three centres perform both alloBMT and autoBMT transplants. One centre performs only allogeneic and one centre performs only autologous transplants. In 1986, the centres formed the Ontario Blood and Marrow Transplant Network and through this network agreed to a strategy for the treatment of NHL. All centres agreed to offer blood or marrow transplantation to patients with aggressive relapsed NHL who demonstrated sensitivity to chemotherapy. Individual centres also had the option of offering blood or marrow transplantation to patients with relapsed indolent lymphoma and/or prior to the demonstration of chemosensitivity after relapse. Eligible patients were offered autotransplant, but were referred for consideration of allotransplant if they had involvement of the bone marrow with lymphoma or an inadequate stem cell/marrow harvest provided they had a related donor. Definitions of marrow involvement and an inadequate autograft were left to the discretion of the individual centres and were not necessarily uniform. There was no standard protocol for patient care, and the intensive therapy regimens were also at the discretion of the treating physicians. Patient data were recorded in a prospective database. This database contains records of all patients who received a bone marrow transplant for NHL in the province of Ontario. No patients were referred outside the province for BMT. We reviewed the database to compare allogeneic and autologous BMT for NHL with respect to the primary endpoint of overall survival. Secondary endpoints included rate of relapse and incidence of treatment-related mortality.
Matched comparison
To further explore potential differences between outcomes after autoBMT and alloBMT, a matched comparison was performed. Patients were matched for prognostic variables affecting survival after autotransplant. A multivariate analysis was performed to determine prognostic variables for survival after autotransplant. By multivariate analysis, the significant independent prognostic variables were age at the time of transplant (P Ͻ 0.0005), disease status at transplant (P = 0.0006), and disease histology (P = 0.0011). Gender, year of transplant and time from diagnosis to transplant were not significant predictors of survival. Based on these variables, autotransplant patients were matched 2:1 to allotransplant patients for age ±5 years, disease status at BMT, and disease histology. Whenever possible, patients were also matched for year of transplant. Matching was performed randomly using a computer-derived scoring system. Only patients for whom all of the above parameters were known were considered for the matched comparison (351 autotransplants and 38 allotransplants). We used the subsets of the matched allo and autograft recipients to assess the primary endpoint of overall survival and secondary endpoints of rate of relapse and incidence of treatmentrelated mortality.
Statistical analysis
Actuarial survival, disease-free survival and risk of relapse were determined by the method of Kaplan and Meier. 10 The log rank test and Cox regression analysis 11 were used to determine prognostic variables for survival after autotransplant. The 2 test was used to compare the populations of allogeneic and autologous patients.
Results
Patient characteristics
Between January 1986 and August 1997, 429 patients underwent BMT for NHL. This included 385 autotransplants and 44 allotransplants. Patient and disease-related characteristics are shown in Table 1 . Sixty-eight percent of the entire cohort had aggressive lymphoma and 32% had indolent lymphoma. Sixty-nine percent received their transplant after demonstrating chemosensitivity after relapse and 31% received their transplant at the time of relapse. The median age of the 429 patients was 46 years (range, 16-73). The median length of follow-up of the surviving patients was 24 months (range, 1 day-108 months). Age, length of follow-up, time from relapse to transplant, and disease status at transplant did not differ between autologous and allogeneic BMT. Forty-five percent of patients who underwent alloBMT and 30% of patients who underwent autoBMT had indolent lymphoma. This difference is significant by 2 analysis (P = 0.04). As expected, no patients undergoing autotransplant experienced graft-versus-host disease (GVHD). Grades 2-4 of acute GVHD and chronic GVHD were experienced by 51% and 54%, respectively, of the allotransplant patients.
Overall survival
Survival data were complete for all 429 patients in the database. The Kaplan-Meier estimate of overall survival after autologous or allogeneic BMT for the entire cohort is shown in Figure 1 . The estimated 3-year survival after autoBMT was 62% (95% CI: 56%-67%). The estimated 3-year survival after alloBMT was 72% (95% CI: 58%-85%). Survival of allo-and autotransplant recipients was not significantly different by the log-rank test (P = 0.53).
Disease-free survival
Disease-free survival did not differ significantly between the two treatments. The Kaplan-Meier estimates for disease-free survival are shown in Figure 2 . The estimated 3- Log-rank P = 0.53 Figure 1 Actuarial survival after autoBMT and alloBMT for NHL.
year disease-free survival after autoBMT was 52% (95% CI: 46%-58%) and the estimated 3-year disease-free survival after alloBMT was 71% (95% CI: 57%-85%). This difference was not significant by the log rank test (P = 0.09). Log-rank P = 0.09 Figure 2 Actuarial progression-free survival after autoBMT and alloBMT.
Relapse rate
(33%) of patients relapsed. Three of 44 (7%) allotransplant recipients relapsed. The Kaplan-Meier estimates of the probabilities of relapse after autologous or allogeneic BMT for the entire cohort is shown in Figure 3 . The estimated three-year risk of relapse after autoBMT was 41% (95% CI: 35%-47%). The estimated three-year risk of relapse after alloBMT was 6% (95% CI: 0%-14%). The difference in rate of relapse was significant by the log-rank test (P = 0.006). Time from transplant (years) Log-rank P = 0.0006
Allo BMT Auto BMT Figure 3 Actuarial probability of relapse after autoBMT and alloBMT.
Treatment-related mortality
The incidence of treatment-related mortality differed between auto-and allo-transplant. After alloBMT, 10 of 44 (23%) patients died from treatment. Ten of 13 (77%) deaths after alloBMT were the result of treatment and two of 13 (15%) died of relapsed disease. Twenty-five of 383 (6%) patients receiving an autotransplant died from treatment. Twenty-five of 132 (19%) deaths after autoBMT were from treatment and 98 of 132 (74%) patients died of relapsed disease. The difference in treatment-related mortality was significant by 2 analysis (P = 0.001).
Matched comparison
To address the heterogeneous nature of the cohort, autotransplant patients were randomly matched 2:1 to the allotransplant patients in priority for (1) age ±5 years; (2) disease status at BMT; (3) disease histology; and (4) year of BMT. Autotransplant patients were matched with allotransplant recipients for all variables in 76% of cases and matched for the significant prognostic variables in 89% of cases. The results of the matched comparison are shown in Table 2 . By matched comparison, survival was equivalent between allo-and autoBMT. The relative risk of death after allotransplant compared with autotransplant was 0.711 (95% CI: 0.039-1.637). A lower relapse rate was seen after alloBMT. Compared with autoBMT, the relative risk for relapse after allotransplant was 0.190 (95% CI: 0.043-0.834). In the matched comparison, treatment-related mortality did not differ significantly between the two transplant modalities. The relative risk of dying from treatmentrelated causes after allotransplant vs autotransplant was 1.425 (95% CI: 0.527-3.851).
Discussion
We reviewed a provincial strategy for the transplantation of NHL to determine whether alloBMT is feasible for patients unsuitable for autoBMT due to marrow involvement or an inadequate stem cell/marrow harvest. In our study, overall survival and disease-free survival were equivalent. As expected, the lower relapse rate after alloBMT was offset by a higher treatment-related mortality. The shape of the Kaplan-Meier survival curves for the two transplant modalities appeared similar as a result of early relapses among the autotransplant patients. Most events occurred within the first 2 years and then the curves reached a plateau. Equivalent disease-free survival has been a consistent finding among the few studies that have compared alloBMT and autoBMT for NHL. 8, 9 These studies, however, did not provide overall survival data.
We observed a lower rate of relapse after alloBMT compared with autoBMT. Others 8, 9 have similar findings, but their reported risks of relapse after both alloBMT and autoBMT were higher than ours. These differences may be due to the inclusion of large numbers of patients with chemotherapy-resistant disease in the other studies. For example, in the study by Ratanatharathorn et al, 9 50% of patients had resistant disease at the time of transplant. Chemotherapy-resistant disease is a known indicator of poor prognosis both for the risk of relapse and overall survival. 3, 12, 13 The lower rate of relapse after alloBMT compared with autoBMT may represent better control of residual disease possibly from a graft-versus-lymphoma effect. Due to the small number of relapses in the alloBMT group, we were unable to determine a correlation between graft-versus-host disease and relapse. Jones et al 14 noted such a correlation between chronic GVHD and relapse rate. Ratanatharathorn et al 9 reported a trend towards improved progression-free survival in patients who developed chronic GVHD.
We performed a matched comparison to address the concern that the equivalent survival was due to the heterogeneity in the cohort. In the matched comparison, overall survival did not differ. Relapse rate was still lower after allotransplant. In the matched comparison, treatmentrelated mortality was higher in the alloBMT group but did not reach significance. This finding is in contrast to the observation for the entire cohort showing that allotransplant patients had a significantly higher treatment-related mortality. This difference appears to result from lower treatment-related mortality among the allotransplant patients with complete follow-up data who were included in the matched comparison. Alternatively, smaller numbers of patients in the matched comparison may provide insufficient power to detect a true difference in treatmentrelated mortality.
There are some limitations to our provincial strategy. First, the patient population was not homogenous. All centres agreed to offer transplants to patients with relapsed aggressive NHL that demonstrated chemosensitivity, but due to the preferences of individual centres, approximately one-third of patients received transplants for indolent lymphoma and/or prior to the demonstration of chemosensitivity after relapse. We attempted to account for this heterogeneity by performing a matched comparison. Second, adherence to the provincial strategy was not centrally monitored. Therefore, it is possible that an occasional patient who qualified for autotransplant received an allotransplant due to patient or physician preferences. Furthermore, some patients with relapsed lymphoma who qualified for a transplant may not have been referred to a transplant centre. Without central monitoring, a histological review of the cases was also not possible. Finally, patients who underwent allotransplant were not considered candidates for autotransplant due to marrow involvement or an inability to obtain a graft. Therefore, even with the matched comparison, it was not possible to match the patient groups
